Merchant Group

📺 @7NewsAustralia has covered our NTI164 trial for Rett Syndrome, highlighting the potential of this treatment to improve key areas such as communication, anxiety, and socialisation. At @NeurotechInt, we remain committed to advancing treatment options for #paediatric neurological disorders. Watch the full story here: youtu.be/dyXda8YM4pU #Neurotech $NTI #RettSyndrome #NTI164 #ClinicalTrials #Biotech #HopeForRett #ASX #BREAKINGNEWS #7NEWS

MST Financial has initiated research coverage on @NeurotechInt, assigning a valuation of $0.60. The MST Healthcare team, led by the highly regarded Senior Analyst Andrew Goodsall and Roy Taouk, highlights the company's current discount compared to its peers at a similar stage of development. The report also emphasises the market opportunities for NTI164 across our four clinical indications: #autism, #PANDAS/#PANS, #RettSyndrome, and cerebral palsy. Read the full $NTI Report here: neurotechinternational.com/w… #ASXnews

In a recent #investor webinar, our Executive Director, Dr Thomas Duthy, shared exciting updates on our progress in developing a treatment for #RettSyndrome. Dr Duthy highlighted the success of our Phase I/II clinical trial (NTIRTT1) using NTI164, a broad-spectrum cannabinoid drug therapy. The trial demonstrated significant clinical benefits and safety in girls with Rett Syndrome. Dr. Duthy expressed his pride in $NTI's achievements, stating, "The company has delivered in spades. We have had three clinical trials in #PANDAS, #PANS, #Autism and now Retts Syndrome. All basically deliver results and we're very proud of that." #ClinicalTrial #Neuroscience #biotech #smallcaps #smallcapstocks #biotechnology

We've received positive results from our Phase I/II clinical trial, NTIRTT1, investigating NTI164, a cannabinoid drug therapy, for Rett Syndrome. The trial, involving 14 female pediatric patients, showed statistically significant clinical improvement with #NTI164 compared to baseline. The primary endpoint, Clinical Global Impression – Improvement (CGI-I) at 12 weeks, was met with a mean improvement of -0.3 (p=0.04), indicating a favorable comparison to the FDA-approved Rett Syndrome drug, DAYBUE™ (trofinetide). All patients completed the 12-week treatment, and data collection is ongoing for further analysis on safety and secondary endpoints. NTI164 has shown promise in other neurological disorders in children like #autism and #PANDAS/PANS. #RettSyndrome, a rare genetic disorder primarily affecting girls, has limited treatment options, making these results significant for potential therapeutic advancements. Read the full $NTI #ASX Announcement here: investi.com.au/api/announcem… #Neurotech #RettSyndromeTrial #CannabinoidTherapy #PediatricNeurology #ClinicalTrialResults #RareDiseaseTreatment #NeurologicalDisorders #MECP2Mutation #DrugDevelopment #HealthcareInnovation #asxnews